FDA accepts less-than-lifetime (LTL) adjustment for nitrosamine impurity limits
- September 25, 2026
On 24 September 2026, the US Food and Drug Administration (FDA) published a guidance update, “Application of Less-Than-Lifetime Adjustment to Nitrosamine Impurities”, confirming that less-than-lifetime (LTL) adjustment factors may now be applied to recommended acceptable intake (AI) limits for nitrosamine impurities in drug products intended for a less-than-lifetime duration of treatment.
Confidently identify additional data sources for genotoxic and carcinogenic endpoints using the latest release of Vitic
- August 5, 2026
Lhasa Limited introduces Vitic (version 2026.1.0), an expertly curated toxicity database with a variety of new data releases to further support insights into carcinogenicity and strengthen existing endpoints.
Zeneth 10.2: structural prioritisation for forced degradation study design
- June 30, 2026
Forced degradation prediction can generate significant results volumes. Soft spots functionality in Zeneth gives analytical chemists a systematic route to the structural areas of an API (active pharmaceutical ingredient) most susceptible to degradation.
Lhasa Limited releases Kaptis 3.1 to strengthen transparency and confidence in carcinogenicity assessment
- June 25, 2026
Lhasa Limited is pleased to announce the release of Kaptis 3.1, offering enhanced guided decision support for carcinogenicity assessment. This update reflects the continued commitment by Lhasa to support transparent, structured and scientifically defensible decision-making in an area where complex data and evolving regulatory expectations can create uncertainty.
Lhasa Limited Intermediates Data Sharing Initiative reaches 43,974 Ames mutagenicity data records in 20th year of improved toxicology
- June 3, 2026
The Lhasa Intermediates Data Sharing Initiative celebrates a significant milestone, its 20th anniversary, along with twenty consecutive years of collated industry donated Ames mutagenicity records.
Replacing animal testing: Lhasa publishes industry framework to support UK strategy implementation
- June 2, 2026
The UK Government’s Replacing Animals in Science strategy marks a pivotal moment for regulatory science, setting out a national ambition to accelerate the development, validation and uptake of non-animal New Approach Methodologies (NAMs).
Lhasa Limited ranked 11th in 2026 UK & Ireland Inspiring Workplaces Awards
- May 28, 2026
Lhasa Limited has been recognised as one of the UK & Ireland’s top Inspiring Workplaces for 2026, ranking joint 11th in the prestigious Inspiring Workplaces Awards.
Achieve reliability in nitrosamine control and formulation with >3000 shared results available in the Lhasa Nitrite Data Sharing Initiative
- May 13, 2026
The Lhasa Nitrites Data Sharing Initiative involves exclusively shared proprietary data, sourced from our consortium members formed from various leading pharmaceutical organisations and excipient manufacturers.
Lhasa Limited launches Acrostic 2.0: Supporting confident, structured read-across support for nitrosamine and systemic toxicity assessments
- May 13, 2026
Acrostic 2.0 introduces enhancements to support scientists in deriving and justifying compound-specific safety decisions regarding nitrosamines and systemic toxicity assessments.
Regulatory expectations continue to evolve.
Lhasa shared excipient database now encompasses over 4000 tolerability records from almost 20 years of pharmaceutical industry collaboration
- April 15, 2026
The Lhasa Excipients Data Sharing Initiative facilitates the anonymous sharing of data on the tolerability of pharmaceutical excipient formulations.
This provides pharmaceutical organisations and drug development companies with the unique ability to access an external, centralised dataset for excipient and vehicle toxicity data whilst remaining anonymous when donating their own records.